The Relationship Between Metformin and Serum Prostate-Specific Antigen Levels

The study examined the impact of metformin on serum prostate-specific antigen (PSA) levels in 326 men with type 2 diabetes, revealing a significant inverse non-linear association between metformin dosage and PSA levels. Higher doses of metformin were linked to lower PSA levels, suggesting a potential influence on prostate biology and a possible reduction in prostate cancer risk. However, the study's cross-sectional design and limited demographic scope restricted causal conclusions, highlighting the need for further research in larger cohorts to confirm these findings and explore their implications for prostate cancer outcomes.